Clinical trial
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
NCT00426803 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00426803 |
|---|---|
| Title | Recombinant Factor VIIa in Acute Intracerebral Haemorrhage |
| Official title | Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Parallel Groups, Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Intracerebral Haemorrhage |
| Intervention type | Drug |
| Interventions | activated recombinant human factor VII |
| Enrollment | 400 |
| Start date | Aug 1, 2002 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Jan 25, 2007 |
| Last update posted | Jan 18, 2017 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Italy, Netherlands, Norway, Singapore, Spain and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: